• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

下咽鳞癌中 B7-H3 的表达作为肿瘤转移和预后的预测指标。

Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis.

机构信息

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Midorigaoka E 2-1-1-1, Asahikawa 078-8510, Japan.

出版信息

Int J Oncol. 2011 May;38(5):1219-26. doi: 10.3892/ijo.2011.949. Epub 2011 Feb 22.

DOI:10.3892/ijo.2011.949
PMID:21344157
Abstract

B7-H3 is a member of the B7 family thought to be a co-regulatory factor of antigen-specific T-cell immune response via co-stimulatory and co-inhibitory receptors. We evaluated its potential expression in head and squamous cell carcinoma (SCC) cell lines, and in clinical tissue samples obtained from 37 patients with human hypopharyngeal SCC. All head and neck SCC cell lines tested expressed both the B7-H3 gene and cell surface protein. The staining intensity of immunoreactivity by tumor cells was blindly evaluated by two head and neck surgeons and the results were categorized into 4 grades according to staining intensity. Eighty-seven percent of patients expressed B7-H3. B7-H3 expression was inversely correlated with the number of tumor infiltrating CD8+ T-cells (r=-0.4339, p=0.023). Patients who developed distant metastasis after tumor-free periods showed significantly higher B7-H3 expression scores compared to patients who did not develop distant metastasis during follow-up periods (p=0.048). Distant metastasis control ratio in patients with strong B7-H3 expression was significantly lower compared to that in patients with no to intermediate B7-H3 expression (p=0.040). Cause-specific survival ratio in patients with strong B7-H3 expression was significantly lower compared to that in patients with no to intermediate B7-H3 expression (p=0.028). Moreover, multivariate analysis revealed that strong B7-H3 expression was an independent prognostic factor in tumor-specific death in hypopharyngeal SCC (hazard ratio: 9.803, confidence interval: 0.018-0.539, p=0.0110).

摘要

B7-H3 是 B7 家族的一员,被认为是通过共刺激和共抑制受体调节抗原特异性 T 细胞免疫反应的协同调节因子。我们评估了其在头颈部鳞状细胞癌(SCC)细胞系和 37 例人类下咽 SCC 患者临床组织样本中的潜在表达。所有测试的头颈部 SCC 细胞系均表达 B7-H3 基因和细胞表面蛋白。两名头颈外科医生对肿瘤细胞免疫反应的染色强度进行了盲法评估,并根据染色强度将结果分为 4 个等级。87%的患者表达 B7-H3。B7-H3 的表达与肿瘤浸润性 CD8+T 细胞的数量呈负相关(r=-0.4339,p=0.023)。在无肿瘤间期后发生远处转移的患者与在随访期间未发生远处转移的患者相比,B7-H3 表达评分显著更高(p=0.048)。B7-H3 表达较强的患者的远处转移控制率明显低于 B7-H3 表达无到中等的患者(p=0.040)。B7-H3 表达较强的患者的无病生存比明显低于 B7-H3 表达无到中等的患者(p=0.028)。此外,多变量分析显示,B7-H3 表达较强是下咽 SCC 肿瘤特异性死亡的独立预后因素(危险比:9.803,置信区间:0.018-0.539,p=0.0110)。

相似文献

1
Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis.下咽鳞癌中 B7-H3 的表达作为肿瘤转移和预后的预测指标。
Int J Oncol. 2011 May;38(5):1219-26. doi: 10.3892/ijo.2011.949. Epub 2011 Feb 22.
2
Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis.B7-H3 在子宫内膜癌中的免疫表达:与肿瘤 T 细胞浸润和预后的关系。
Gynecol Oncol. 2012 Jan;124(1):105-11. doi: 10.1016/j.ygyno.2011.09.012. Epub 2011 Oct 6.
3
B7-H3 and B7-H4 expression in non-small-cell lung cancer.非小细胞肺癌中B7-H3和B7-H4的表达
Lung Cancer. 2006 Aug;53(2):143-51. doi: 10.1016/j.lungcan.2006.05.012. Epub 2006 Jun 19.
4
Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.喉和下咽鳞状细胞癌的区域转移延迟、远处转移及第二原发性恶性肿瘤
Laryngoscope. 2001 Jun;111(6):1079-87. doi: 10.1097/00005537-200106000-00028.
5
B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells.B7-H3 在胃癌中的表达:一种新型的分子血液标记物,用于检测循环肿瘤细胞。
Cancer Sci. 2011 May;102(5):1019-24. doi: 10.1111/j.1349-7006.2011.01877.x. Epub 2011 Feb 17.
6
[Expression and clinical significance of costimulatory molecule B7-H3 mRNA and B7-H3 protein in gastric carcinoma].共刺激分子B7-H3 mRNA及B7-H3蛋白在胃癌中的表达及临床意义
Zhonghua Wei Chang Wai Ke Za Zhi. 2007 Sep;10(5):458-62.
7
Transgenic B7-H3 therapy induces tumor-specific immune response in human oral squamous cell cancer: an in vitro study.转基因B7-H3疗法在人口腔鳞状细胞癌中诱导肿瘤特异性免疫反应:一项体外研究。
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Nov;106(5):721-8. doi: 10.1016/j.tripleo.2008.08.012.
8
Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions.人类肌肉细胞表达共刺激分子B7-H3,该分子可调节肌肉与免疫的相互作用。
Arthritis Rheum. 2008 Nov;58(11):3600-8. doi: 10.1002/art.23997.
9
[Regional failure of hypopharyngeal squamous cell carcinoma].[下咽鳞状细胞癌的区域性功能衰竭]
Cancer Radiother. 2004 Dec;8(6):352-7. doi: 10.1016/j.canrad.2004.09.005.
10
B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response.B7-h4 在人类黑色素瘤中的表达:与患者生存和抗肿瘤免疫反应的关联。
Clin Cancer Res. 2011 May 15;17(10):3100-11. doi: 10.1158/1078-0432.CCR-10-2268. Epub 2011 Mar 4.

引用本文的文献

1
B7-H3 in Cancer Immunotherapy-Prospects and Challenges: A Review of the Literature.癌症免疫治疗中的B7-H3:前景与挑战——文献综述
Cells. 2025 Aug 6;14(15):1209. doi: 10.3390/cells14151209.
2
Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer.靶向B7-H3的新型三特异性杀伤细胞衔接器增强自然杀伤细胞对头颈部癌的抗肿瘤活性。
J Immunother Cancer. 2025 Jul 23;13(7):e011370. doi: 10.1136/jitc-2024-011370.
3
Prognostic Significance of B7H3 Expression in Solid Tumors: A Systematic Review and Meta-Analysis.
B7H3在实体瘤中的预后意义:一项系统评价和Meta分析
Int J Mol Sci. 2025 Mar 26;26(7):3044. doi: 10.3390/ijms26073044.
4
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12).一项评估 spartalizumab(PDR001)在复发或转移性食管鳞癌患者中的疗效和安全性的 2 期研究(KCSG HN18-17,K-MASTER 项目 12)。
Oncoimmunology. 2024 Jun 24;13(1):2371563. doi: 10.1080/2162402X.2024.2371563. eCollection 2024.
5
The Comprehensive Characterization of B7-H3 Expression in the Tumor Microenvironment of Lung Squamous Cell Carcinoma: A Retrospective Study.肺鳞状细胞癌肿瘤微环境中B7-H3表达的综合特征:一项回顾性研究
Cancers (Basel). 2024 Jun 4;16(11):2140. doi: 10.3390/cancers16112140.
6
A new marker constructed from immune-related lncRNA pairs can be used to predict clinical treatment effects and prognosis: in-depth exploration of underlying mechanisms in HNSCC.一种由免疫相关 lncRNA 对构建的新标志物可用于预测临床治疗效果和预后:头颈部鳞状细胞癌中潜在机制的深入探讨。
World J Surg Oncol. 2023 Aug 17;21(1):250. doi: 10.1186/s12957-023-03066-x.
7
B7-H3 Associates with IMPDH2 and Regulates Cancer Cell Survival.B7-H3与肌苷酸脱氢酶2相关并调节癌细胞存活。
Cancers (Basel). 2023 Jul 7;15(13):3530. doi: 10.3390/cancers15133530.
8
The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.B7/CD28 免疫调节剂的一致破坏预测口腔癌的预后。
Int J Mol Sci. 2023 Mar 21;24(6):5931. doi: 10.3390/ijms24065931.
9
Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects.头颈部鳞状细胞癌的免疫调节治疗:最新进展和临床前景。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221150559. doi: 10.1177/15330338221150559.
10
Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers.癌症治疗中的检查点抑制剂:对头颈部癌症的临床益处
Cancers (Basel). 2022 Oct 11;14(20):4985. doi: 10.3390/cancers14204985.